LNP Stability Testing: A Practical Protocol for PEG-Lipid Nanoparticles

Formulating a lipid nanoparticle that works on Day 1 is one challenge. Ensuring it still works on Day 90, Day 180, or Day 365 is another entirely. LNP stability testing is where promising formulations either prove their viability as drug products or reveal hidden weaknesses — particle aggregation, cargo degradation, PEG shedding, or lipid oxidation — that only manifest over time.

This article provides a practical, implementable stability testing protocol for PEG-lipid nanoparticle formulations. It covers study design, storage conditions, testing timepoints, analytical methods, common degradation pathways, and how PEG-lipid selection influences long-term stability. For the broader context of LNP formulation design, see our complete LNP formulation guide.

Why LNP Stability Is Challenging

LNPs are thermodynamically metastable systems. Unlike covalently bonded drug molecules, LNPs are held together by relatively weak hydrophobic interactions, van der Waals forces, and electrostatic contacts. These non-covalent forces are sufficient to maintain the nanoparticle structure under favorable conditions but are vulnerable to disruption by temperature changes, dilution, pH shifts, and oxidative stress.

Several factors make LNP stability particularly demanding:

• Nucleic acid cargo is inherently labile. mRNA is susceptible to hydrolysis (especially at the 2’-OH of ribose), oxidation, and enzymatic degradation. Even trace RNase contamination can destroy the payload.
• The PEG-lipid layer is dynamic. PEG-lipids desorb from the particle surface over time, and the rate depends on the lipid anchor, PEG chain length, temperature, and the surrounding medium. PEG loss changes particle size, surface properties, and biological behavior.
• Lipids oxidize. Unsaturated lipid components — particularly DOPE (if used as helper lipid) and certain ionizable lipids — are susceptible to peroxidation, which generates cytotoxic degradation products and disrupts membrane integrity.
• Fusion and aggregation occur. As the PEG layer thins due to shedding, the steric barrier weakens, and particles can fuse or aggregate. This increases particle size, broadens PDI, and reduces potency.

Designing a Stability Study: Key Elements

Storage Conditions

A thorough stability study evaluates LNP performance across multiple temperature conditions. The choice of conditions depends on your target product profile and regulatory expectations.

For early-stage formulation screening, a simplified protocol at 4°C and 37°C captures the most decision-relevant information. For IND-enabling studies, include all five conditions per ICH Q1A and Q5C guidelines.

Testing Timepoints

Always include Day 0 measurements immediately after formulation as the reference baseline. Ensure sufficient sample volume is aliquoted at Day 0 to avoid repeated freeze-thaw of stock material.

Sample Handling

• Aliquot at Day 0. Prepare individual aliquots for each timepoint and condition to avoid repeated sampling from a single container.
• Use low-binding containers. Polypropylene or glass with low protein/lipid binding. Avoid polystyrene.
• Protect from light. LNPs containing unsaturated lipids are photosensitive. Store in amber vials or wrapped in foil.
• Control headspace. Minimize air exposure in vials to reduce oxidation. Nitrogen overlay is recommended for long-term studies.

Analytical Methods for Stability Assessment

Each testing timepoint should measure the following panel of attributes. Together, these data reveal whether the LNP is maintaining its target product profile or drifting toward a degraded state.

1. Particle Size and PDI (DLS)

Instrument: Malvern Zetasizer, Wyatt DynaPro, or equivalent Sample preparation: Dilute to ~0.1–0.5 mg/mL total lipid in PBS pH 7.4; measure in triplicate at 25°C Acceptance criteria: Size within ±20% of Day 0; PDI < 0.25

Size growth is the earliest and most sensitive indicator of instability. An increase of 10–15 nm from baseline warrants investigation. An increase of >30 nm or PDI exceeding 0.3 typically indicates particle fusion or aggregation and is a formulation failure.

2. Encapsulation Efficiency (RiboGreen Assay)

Instrument: Fluorescence plate reader Reagents: Quant-iT RiboGreen RNA Assay Kit (Thermo Fisher) Protocol: Measure fluorescence of intact LNPs (free RNA only) and lysed LNPs (0.5% Triton X-100, total RNA). EE% = (Total − Free) / Total × 100. Acceptance criteria: EE% decrease of <10 percentage points from Day 0

Declining EE% during storage indicates cargo leakage — nucleic acid escaping from the LNP interior. This is often correlated with PEG shedding (loss of surface barrier) or lipid phase transitions at the storage temperature.

3. Nucleic Acid Integrity

Instrument: Agilent BioAnalyzer, Fragment Analyzer, or capillary gel electrophoresis Acceptance criteria: mRNA integrity >70% (application-dependent)

mRNA integrity is the most potency-relevant stability metric. Hydrolytic degradation at the phosphodiester backbone fragments the mRNA, producing non-functional truncated species. The rate of hydrolysis is temperature-dependent (Arrhenius behavior) and pH-dependent — mRNA is most stable at pH 6.0–7.0 and least stable under acidic conditions.

4. PEG-Lipid Content (HPLC or LC-MS)

Instrument: HPLC with ELSD or CAD; LC-MS for definitive identification Column: C4 or C8 reverse phase Acceptance criteria: PEG-lipid content within ±15% of Day 0

PEG-lipid loss from the formulation — through desorption into solution or adsorption onto container surfaces — is a critical stability-limiting factor. As PEG surface coverage decreases, particles lose their steric barrier, leading to aggregation, increased opsonization, and altered biodistribution.

Monodisperse PEG-lipids produce a single sharp HPLC peak that is straightforward to quantify and track over time. Polydisperse PEG-lipids produce broad, sometimes multimodal peaks where small changes in total content are masked by peak shape variability.

5. Zeta Potential

Instrument: Zetasizer (ELS mode) Acceptance criteria: Within ±5 mV of Day 0

Shifts in zeta potential during storage may indicate PEG loss (exposing charged lipid surfaces), pH drift in the buffer, or ionizable lipid degradation.

6. Visual Inspection

Simple but important. Look for: – Turbidity increase — indicates aggregation – Phase separation — formulation failure – Color change — lipid oxidation (yellowing) – Particulates — visible aggregates

PEG Shedding Kinetics: The Hidden Stability Variable

PEG shedding — the desorption of PEG-lipid molecules from the LNP surface into the surrounding medium — is one of the most consequential processes during LNP storage and in vivo performance. Understanding its kinetics is essential for predicting shelf life and choosing the right PEG-lipid.

Mechanism

PEG-lipid molecules are anchored in the LNP membrane by their hydrophobic acyl chains. The equilibrium between membrane-inserted and solution-phase PEG-lipid is governed by the free energy of membrane insertion, which depends primarily on:

1. Acyl chain length. C18 anchors (DSPE) have ~4 kcal/mol greater membrane insertion energy than C14 anchors (DMG), translating to ~100-fold slower desorption kinetics.
2. Temperature. Higher temperatures increase membrane fluidity and accelerate desorption. The Arrhenius activation energy for DMG-PEG shedding is approximately 15–20 kcal/mol.
3. PEG chain length. Longer PEG chains increase the hydrophilic pull, modestly accelerating desorption.
4. Medium composition. Serum proteins, lipoprotein particles, and other lipid acceptors in biological fluids accelerate PEG shedding by providing a thermodynamic sink for desorbed PEG-lipid.

Measured Shedding Rates

Approximate values from published literature; actual rates depend on formulation composition and buffer conditions.

Implications for Shelf Life

For formulations using C14-anchored PEG-lipids (DMG-PEG variants), significant PEG shedding occurs even at 4°C over weeks to months. This is a primary driver of particle size growth during refrigerated storage. Strategies to mitigate PEG shedding during storage include:

• Frozen storage (−20°C or −80°C): Effectively halts PEG desorption by immobilizing the lipid membrane.
• Higher initial PEG-lipid loading: Starting with 2–3 mol% provides a buffer against shedding, though this affects initial particle size.
• DSPE-anchored PEG-lipids: mPEG44-DSPE sheds orders of magnitude more slowly, dramatically improving refrigerated shelf life — but at the cost of altered in vivo pharmacokinetics.
• Cryoprotectant formulation: 10% sucrose or trehalose enables lyophilization, creating a dry powder with stability measured in years.

For more on how PEG chain length affects nanoparticle properties, see our article on nanoparticle PEG weight considerations.

Common Degradation Pathways

Understanding how LNPs degrade helps you design studies that detect problems early and formulate around known failure modes.

1. Particle Aggregation and Fusion

Root cause: PEG shedding reduces steric barrier; colloidal stability lost Detection: Size increase by DLS, PDI increase, visual turbidity Mitigation: Frozen storage, higher PEG-lipid loading, DSPE-based PEG-lipid, sucrose cryoprotectant

2. Nucleic Acid Hydrolysis

Root cause: Water-mediated phosphodiester cleavage; accelerated by acidic pH, divalent cations, elevated temperature Detection: Fragment Analyzer (decreased intact mRNA peak, increased fragments) Mitigation: Formulate in pH 7.0–7.5 buffer; remove divalent cations; store frozen; consider lyophilization

3. Lipid Oxidation

Root cause: Peroxidation of unsaturated acyl chains (DOPE, some ionizable lipids) by dissolved oxygen or light Detection: TBARS assay, lipid hydroperoxide assay, appearance of aldehyde degradation products by LC-MS Mitigation: Nitrogen overlay, amber storage, antioxidant excipients (α-tocopherol, EDTA), use of saturated helper lipid (DSPC over DOPE)

4. PEG-Lipid Hydrolysis

Root cause: Ester bond hydrolysis in DMG-PEG (the ester linking the glycerol backbone to the PEG chain) Detection: LC-MS (appearance of free PEG and free DMG fragments) Mitigation: pH control (neutral buffer), low temperature storage. Note: DSPE-PEG uses an amide bond that is significantly more hydrolysis-resistant.

5. Cargo Leakage

Root cause: Membrane permeabilization from PEG shedding, lipid oxidation, or phase transitions Detection: Declining EE% over time (RiboGreen assay) Mitigation: Frozen storage, optimized lipid composition, PEG-lipid with appropriate anchor

Sample Stability Study Design

The following table outlines a practical stability study for a development-stage mRNA LNP formulation:

Sample requirements: ~200 μL per DLS measurement, ~50 μL per RiboGreen assay, ~5 μL per integrity measurement, ~200 μL per HPLC measurement. Plan for 500–1,000 μL per aliquot to accommodate the full panel plus reserves.

Formulation buffer: 20 mM Tris-HCl pH 7.4, 8% sucrose (or similar cryoprotectant-containing buffer for frozen storage).

Practical Tips for Stability Testing

Start measuring immediately. Day 0 data establishes your reference. Delays of even 24 hours can introduce bias, especially at ambient temperature.

Include freeze-thaw cycling. Many LNP products will undergo freeze-thaw during distribution. Test 1, 3, 5, and 10 cycles and measure the full analytical panel after each.

Track PEG-lipid content explicitly. Many groups focus on size and encapsulation while ignoring PEG-lipid quantification. Yet PEG loss is often the root cause of the size increases and EE% drops they observe. Tracking PEG-lipid content connects the cause to the effect.

Use the accelerated condition to rank candidates. If you’re choosing between formulations, a 28-day study at 25°C or 37°C differentiates candidates much faster than waiting 6 months at 4°C. The formulation that performs best under stress will almost always have the best long-term refrigerated stability.

Don’t forget the container. Glass type I vials, COP (cyclic olefin polymer) syringes, and polypropylene tubes all interact differently with lipid nanoparticles. PEG-lipid can adsorb to certain surfaces. Include container closure compatibility in your stability program.

PurePeg’s monodisperse PEG-lipids — including DMG-PEG24 and DMG-PEG45 — provide a consistent starting point for stability studies by eliminating the lot-to-lot PEG chain length variability that confounds longitudinal stability data with polydisperse reagents. Browse the full PEG-Lipid catalog for all available options.

Designing a stability program for your LNP formulation? PurePeg’s monodisperse PEG-lipids deliver the batch-to-batch consistency essential for meaningful stability comparisons. Explore the PEG-Lipid catalog or contact our team at 1-888-331-8188 to discuss your requirements.